T13564 |
AZ7550
|
1421373-99-0
|
97.07%
|
|
AZ7550, an active metabolite of AZD9291, inhibits the activity of IGF1R (IC50: 1.6 μM).
|
T28911 |
Tafetinib
|
1032265-57-8
|
96.66%
|
|
Tafetinib (SIM-010603) is a novel potent and orally available tyrosine kinase inhibitor with anti-angiogenic and anti-tumour activity.
|
T6266 |
PP2
|
172889-27-9
|
95.65%
|
|
PP2 (AG 1879,AGL 1879) is a effective inhibitor of Lck/Fyn (IC50:4/5 nM) , ~100-fold less potent to EGFR, inactive for ZAP-70, PKA and JAK2.
|
T1506 |
Vidarabine
|
5536-17-4
|
100%
|
|
Vidarabine (Adenine Arabinoside) is a nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum...
|
T62902 |
NDI-034858
|
2272904-53-5
|
100%
|
|
NDI-034858 (TAK-279) is a tyrosine kinase 2 (TYK2) inhibitor (Kd<200 pM) that targets the JH2 structural domain of Tyk2 for the treatment of autoimmune diseases ...
|
T1181 |
Gefitinib
|
184475-35-2
|
100%
|
|
Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations. Gefitinib has antitumor activity a...
|
T4391 |
Syk Inhibitor II dihydrochloride
|
227449-73-2
|
100%
|
|
Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase that, upon phosphorylation, binds to immunoreceptor tyrosine-based activation motifs of FcRγ chain...
|
T60094 |
SU 4981
|
186610-88-8
|
100%
|
|
SU 4981 is an inhibitor of VEGFR and a modulator of tyrosine kinase activity.
|
T17220 |
Vecabrutinib
|
1510829-06-7
|
100%
|
|
Vecabrutinib (SNS-062) is a potent and noncovalent BTK and ITK inhibitor (Kd: 0.3 nM and 2.2 nM, respectively). Vecabrutinib displays an IC50 of 24 nM for ITK.
|
T1936 |
Alectinib
|
1256580-46-7
|
98%
|
|
Alectinib (RG-7853) is an orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity.
|
T15096 |
Delgocitinib
|
1263774-59-9
|
98%
|
|
Delgocitinib (Corectim(Delgocitinib)) is a potent and specific JAK inhibitor with an IC50 value of 2.8, 2.6, 13 and 58 nM against JAK1, JAK2, JAK3 and Tyk2. Delg...
|
T62447 |
Paltimatrectinib
|
2353522-15-1
|
98%
|
|
Paltimatrectinib (PBI-200) is a potent tyrosine kinase inhibitor with anticancer activity that inhibits myosin-related kinase A (TrkA).Paltimatrectinib is used i...
|
T6294 |
NVP-BSK805 2HCl (1092499-93-8(free base))
|
T6294
|
98%
|
|
NVP-BSK805 2HCl (1092499-93-8(free base)) (BSK 805)(IC50=0.5 nM), a specific and effective ATP-competitive JAK2 inhibitor, is more than 20-fold specificity over ...
|
T6380 |
AMG 900
|
945595-80-2
|
98%
|
|
AMG 900 is a potent and highly selective pan-Aurora kinases inhibitor for Aurora A/B/C with IC50 of 5 nM/4 nM /1 nM. It is >10-fold selective for Aurora kinases ...
|
T6343 |
Geldanamycin
|
30562-34-6
|
98%
|
|
Geldanamycin, an HSP90 inhibitor (Kd: 1.2 μM), specifically disrupts glucocorticoid receptor (GR)/HSP association.
|
T2360 |
Baricitinib phosphate
|
1187595-84-1
|
98%
|
|
Baricitinib phosphate (INCB028050) is a selective orally bioavailable JAK1/JAK2 inhibitor.
|
T61494 |
JAK-IN-21
|
2445499-20-5
|
98%
|
|
JAK-IN-21 is a selective and potent JAK inhibitor that inhibits JAK1, JAK2, J2V617F and TYK2 with IC50 values of 1.73, 2.04, 109 and 62.9 nM, respectively.
|
TQ0010 |
Brepocitinib
|
1883299-62-4
|
98%
|
|
Brepocitinib (PF-06700841) is a potent dual JAK1/TYK2 inhibitor (IC50s: 17 nM/23 nM). Brepocitinib also inhibits JAK2/3 (IC50s: 77 nM/6.49 μM).
|